Pacira BioSciences, Inc. Total Assets
Pacira BioSciences, Inc. total assets. Based on the latest financial reports, Pacira BioSciences, Inc. (PCRX) holds total assets worth $1.24 Billion USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Pacira BioSciences, Inc. stock valuation for the company's overall valuation and market capitalisation.
Total Assets of Pacira BioSciences, Inc. (2008–2025)
Total assets of Pacira BioSciences, Inc. from 2008 to 2025. This chart illustrates how Pacira BioSciences, Inc.'s total assets have evolved over time, based on quarterly financial data. See Pacira BioSciences, Inc. (PCRX) stock price for real-time trading data and today's change.
Pacira BioSciences, Inc. - Asset Composition Analysis
Pacira BioSciences, Inc. Total Assets Breakdown (December 2025)
Pacira BioSciences, Inc. total assets breakdown as of December 2025. Pacira BioSciences, Inc.'s total assets of $1.24 Billion consist of 43.3% current assets and 56.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 12.5% |
| Accounts Receivable | $124.07 Million | 9.8% |
| Inventory | $152.86 Million | 12.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $368.10 Million | 29.1% |
| Goodwill | $20.21 Million | 1.6% |
Asset Composition Trend (2008–2025)
This chart illustrates how Pacira BioSciences, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Pacira BioSciences, Inc. current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Pacira BioSciences, Inc.'s current assets represent 43.3% of total assets in 2025, an increase from 38.3% in 2008.
- Cash Position: Cash and equivalents constituted 12.5% of total assets in 2025, down from 24.5% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 30.0% of total assets, an increase from 25.0% in 2008.
- Asset Diversification: The largest asset category is intangible assets at 29.1% of total assets.
Pacira BioSciences, Inc. Competitors by Total Assets
Key competitors of Pacira BioSciences, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Galderma Group N
SW:GALD
|
Switzerland | CHF12.88 Billion |
|
Enzymatica publ AB
ST:ENZY
|
Sweden | Skr149.24 Million |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥13.98 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥10.50 Billion |
Pacira BioSciences, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.04 | 2.38 | 3.64 |
| Quick Ratio | 3.94 | 1.91 | 3.34 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $493.20 Million | $432.45 Million | $596.56 Million |
Pacira BioSciences, Inc. - Advanced Valuation Insights
This section examines the relationship between Pacira BioSciences, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.54 |
| Latest Market Cap to Assets Ratio | 0.81 |
| Asset Growth Rate (YoY) | -18.6% |
| Total Assets | $1.26 Billion |
| Market Capitalization | $1.02 Billion USD |
Valuation Analysis
Near Book Valuation: The market values Pacira BioSciences, Inc.'s assets close to their book value (0.81x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Pacira BioSciences, Inc.'s assets decreased by 18.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Pacira BioSciences, Inc. (2008–2025)
The table below shows the annual total assets of Pacira BioSciences, Inc. from 2008 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $1.26 Billion | -18.58% |
| 2024-12-31 | $1.55 Billion | -1.33% |
| 2023-12-31 | $1.57 Billion | -6.35% |
| 2022-12-31 | $1.68 Billion | -18.99% |
| 2021-12-31 | $2.08 Billion | +62.83% |
| 2020-12-31 | $1.27 Billion | +53.36% |
| 2019-12-31 | $831.07 Million | +20.56% |
| 2018-12-31 | $689.35 Million | +9.70% |
| 2017-12-31 | $628.37 Million | +60.52% |
| 2016-12-31 | $391.47 Million | +0.47% |
| 2015-12-31 | $389.62 Million | +19.49% |
| 2014-12-31 | $326.07 Million | +92.01% |
| 2013-12-31 | $169.82 Million | +51.55% |
| 2012-12-31 | $112.05 Million | -1.27% |
| 2011-12-31 | $113.49 Million | +70.50% |
| 2010-12-31 | $66.56 Million | +51.44% |
| 2009-12-31 | $43.95 Million | -13.03% |
| 2008-12-31 | $50.54 Million | -- |
About Pacira BioSciences, Inc.
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension ind… Read more